Zacks: Brokerages Anticipate Coherus Biosciences Inc (CHRS) to Announce -$0.82 Earnings Per Share

Share on StockTwits

Equities research analysts predict that Coherus Biosciences Inc (NASDAQ:CHRS) will announce earnings per share (EPS) of ($0.82) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Coherus Biosciences’ earnings. The lowest EPS estimate is ($0.90) and the highest is ($0.75). Coherus Biosciences posted earnings per share of ($0.84) during the same quarter last year, which suggests a positive year-over-year growth rate of 2.4%. The firm is expected to issue its next earnings results on Thursday, March 14th.

According to Zacks, analysts expect that Coherus Biosciences will report full-year earnings of ($3.12) per share for the current fiscal year, with EPS estimates ranging from ($3.20) to ($3.04). For the next year, analysts anticipate that the firm will report earnings of ($1.42) per share, with EPS estimates ranging from ($2.16) to $0.02. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that that provide coverage for Coherus Biosciences.

Coherus Biosciences (NASDAQ:CHRS) last released its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.08).

Several equities analysts have recently commented on the company. Zacks Investment Research downgraded Coherus Biosciences from a “hold” rating to a “sell” rating in a research report on Tuesday, December 4th. BidaskClub raised Coherus Biosciences from a “sell” rating to a “hold” rating in a research report on Thursday, January 31st. Finally, ValuEngine raised Coherus Biosciences from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $27.20.

NASDAQ:CHRS traded down $0.30 on Monday, hitting $14.08. The company’s stock had a trading volume of 574,434 shares, compared to its average volume of 721,970. The company has a quick ratio of 5.31, a current ratio of 5.31 and a debt-to-equity ratio of 8.29. The firm has a market capitalization of $957.86 million, a price-to-earnings ratio of -3.14 and a beta of 3.66. Coherus Biosciences has a one year low of $8.32 and a one year high of $20.66.

Hedge funds have recently modified their holdings of the business. Tower Research Capital LLC TRC acquired a new stake in shares of Coherus Biosciences in the 2nd quarter valued at $118,000. Roman Butler Fullerton & Co. acquired a new stake in shares of Coherus Biosciences in the 4th quarter valued at $122,000. State Board of Administration of Florida Retirement System boosted its holdings in shares of Coherus Biosciences by 16.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 22,095 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 3,122 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Coherus Biosciences in the 3rd quarter valued at $282,000. Finally, Boston Advisors LLC boosted its holdings in shares of Coherus Biosciences by 12.7% in the 4th quarter. Boston Advisors LLC now owns 33,060 shares of the biotechnology company’s stock valued at $299,000 after purchasing an additional 3,725 shares in the last quarter. 93.39% of the stock is currently owned by hedge funds and other institutional investors.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc, a biosimilar company, develops and commercializes various therapeutic products worldwide. The company engages in the development of late-stage clinical products, including CHS-1701 pegfilgrastim biosimilar, a granulocyte colony-stimulating factor product candidate; CHS-1420 adalimumab biosimilar, an anti-tumor necrosis factor product candidate; and CHS-0214, an etanercept biosimilar for rheumatoid arthritis and psoriasis.

Featured Story: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Coherus Biosciences (CHRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply